588702-68-5

Basic information

• Product Name: methyl 2-(trifluoromethyl)isonicotinate
• Synonyms: methyl 2-(trifluoromethyl)isonicotinate;Methyl 2-(trifluoroMethyl)pyridine-4-carboxylate;Methyl 2-(trifluoromethyl)pyridine-4-carboxylate, 4-(Methoxycarbonyl)-2-(trifluoromethyl)pyridine;2-(TrifluoroMethyl)pyridine-4-carboxylic acid Methyl ester;2-(Trifluoromethyl)-4-pyridinecarboxylic acid methyl ester;isonicotinate;Methyl 2-(trifluoromethyl)
• CAS NO: 588702-68-5
• Molecular Formula: C8H6F3NO2
• Molecular Weight: 205.1339496
• Mol File: 588702-68-5.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 213.9±40.0 °C(Predicted)
• Appearance: Colorless/Liquid
• Density: 1.331±0.06 g/cm3(Predicted)
• Storage Temp.: Inert atmosphere,Room Temperature
• PKA: -1.56±0.20(Predicted)
• CAS DataBase Reference: methyl 2-(trifluoromethyl)isonicotinate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 2-(trifluoromethyl)isonicotinate(588702-68-5)
• EPA Substance Registry System: methyl 2-(trifluoromethyl)isonicotinate(588702-68-5)

Safety Data

• Hazardous Substances Data: 588702-68-5(Hazardous Substances Data)

Usage

General Description

Methyl 2-(trifluoromethyl)isonicotinate is a chemical compound characterized by having a trifluoromethyl group attached to it. It falls under the category of isonicotinic esters and is primarily used in the synthesis of various pharmaceutical drugs, including anti-inflammatory and anti-anxiety medications. It exhibits a key role in organic chemistry for the construction of intricate chemical structures. This chemical compound also exhibits potential use in the realm of biochemistry and pharmacology research. As with many chemical substances, it needs to be handled with care due to its potential health hazards.

InChI:InChI=1S/C8H6F3NO2/c1-14-7(13)5-2-3-12-6(4-5)8(9,10)11/h2-4H,1H3

Upstream product

• 186581-53-3 diazomethane 
• 124-38-9 carbon dioxide 
• 368-48-9 2-(trifluoromethyl)pyridine 
• 67-56-1 methanol 
• 131747-41-6 2-(trifluoromethyl)-4-pyridinecarboxylic acid 
• 201230-82-2 carbon monoxide 
• 1610419-49-2 trifluoromethanesulfonic acid 2-trifluoromethylpyridin-4-yl ester 
• 1263378-63-7 4-bromo-2-trifluoromethylpyridine hydrobromide 
• 590371-73-6 2-(trifluoromethyl)pyridine-4-iodide 
• 131748-14-6 4-chloro-2-trifluoromethylpyridine 
• 916210-02-1 2-(trifluoromethyl)pyridine-4-carbonitrile 
• 170886-13-2 4-hydroxy-2-trifluoromethylpyridine 
• 58481-10-0 2-iodopyridine-4-carboxylic acid 
• 134579-47-8 methyl 2-iodoisonicotinate 

Downstream Products

• 916304-20-6 2-trifluoromethyl-4-(aminomethyl)pyridine 

Relevant articles and documents

QUINUCLIDINONE ANALOGUES AS ANTICANCER AGENTS

The disclosure includes compounds of Formula (I) and Formula(A) wherein R1, R2, R3, m, n, k, and L are defined herein. Also disclosed are methods for treating a neoplastic disease, autoimmune disease, or an inflammatory disorder with these compounds.

Efficient copper-catalyzed trifluoromethylation of aromatic and heteroaromatic iodides: The beneficial anchoring effect of borates

Efficient copper-catalyzed trifluoromethylation of aromatic iodides was achieved with TMSCF3 in the presence of trimethylborate. The Lewis acid was used to anchor the in situ generated trifluoromethyl anion and suppress its rapid decomposition. Broad applicability of the new trifluoromethylating reaction was demonstrated in the functionalization of different aromatic and heteroaromatic iodides.

SUBSTITUTED PYRAZOLOQUINAZOLINONES AND PYRROLOQUINAZOLINONES AS ALLOSTERIC MODULATORS OF GROUP II METABOTROPIC GLUTAMATE RECEPTORS

The present invention relates to the pyrazoloquinazolinone and pyrroloquinazolinone derivatives of the general formula (I), as well as pharmaceutical compositions containing them, and their use in the treatment and/or prophylaxis of conditions associated with altered glutamatergic signalling and/or functions, and/or conditions which can be affected by alteration of glutamate level or signalling in mammals, in particular their use in the treatment and/or prophylaxis of acute and chronic neurological and/or psychiatric disorders.